My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 152

    1.

    Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program.

    Hernan WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, Lachin JM, Engelgau MM; Diabetes Prevention Program Research Group.

    Diabetes Care. 2003 Jan;26(1):36-47.PMID: 12502656 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.

    Diabetes Prevention Program Research Group.

    Diabetes Care. 2003 Sep;26(9):2518-23.PMID: 12941712 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.

    Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE; Diabetes Prevention Program Research Group.

    Ann Intern Med. 2005 Mar 1;142(5):323-32.PMID: 15738451 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom.

    Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ.

    Clin Ther. 2004 Feb;26(2):304-21.PMID: 15038953 [PubMed - indexed for MEDLINE]Related articles

    5.

    Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.

    Eddy DM, Schlessinger L, Kahn R.

    Ann Intern Med. 2005 Aug 16;143(4):251-64.PMID: 16103469 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP).

    Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z.

    Diabetes Care. 2007 Oct;30(10):2548-52. Epub 2007 Aug 1.PMID: 17670917 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations]

    Flórez H.

    Invest Clin. 1997 Mar;38(1):39-52. Review. Spanish. PMID: 9235072 [PubMed - indexed for MEDLINE]Related articles

    8.

    Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.

    Caro JJ, Getsios D, Caro I, Klittich WS, O'Brien JA.

    Diabet Med. 2004 Nov;21(11):1229-36.PMID: 15498090 [PubMed - indexed for MEDLINE]Related articles

    9.

    [Cost-effective analysis of preventive treatment on diabetes]

    Hu Y, Chen SY, Wang JY.

    Zhonghua Liu Xing Bing Xue Za Zhi. 2004 May;25(5):431-4. Chinese. PMID: 15231174 [PubMed - indexed for MEDLINE]Related articles

    10.

    An update on the Diabetes Prevention Program.

    Ratner RE; Diabetes Prevention Program Research.

    Endocr Pract. 2006 Jan-Feb;12 Suppl 1:20-4. Review.PMID: 16627375 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.

    Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, Andres R, Saudek C, Edelstein SL, Arakaki R, Murphy MB, Shamoon H; Diabetes Prevention Program Research Group.

    Diabetes. 2005 Aug;54(8):2404-14.PMID: 16046308 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.

    Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, Fowler S, Kahn SE; Diabetes Prevention Program Research Group.

    J Clin Endocrinol Metab. 2008 Dec;93(12):4774-9. Epub 2008 Sep 30.PMID: 18826999 [PubMed - indexed for MEDLINE]Related articles

    13.

    Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.

    Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, Temprosa M; Diabetes Prevention Program Research Group.

    Diabetes Care. 2005 Apr;28(4):888-94.PMID: 15793191 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    [Progress in the prevention of type 2 diabetes]

    Schernthaner G.

    Wien Klin Wochenschr. 2003 Nov 28;115(21-22):745-57. Review. German. PMID: 14743578 [PubMed - indexed for MEDLINE]Related articles

    15.

    An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes.

    Ackermann RT, Marrero DG, Hicks KA, Hoerger TJ, Sorensen S, Zhang P, Engelgau MM, Ratner RE, Herman WH.

    Diabetes Care. 2006 Jun;29(6):1237-41.PMID: 16732002 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.

    Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group.

    Ann Intern Med. 2005 Apr 19;142(8):611-9.PMID: 15838067 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    The potential of metformin for diabetes prevention.

    Slama G.

    Diabetes Metab. 2003 Sep;29(4 Pt 2):6S104-11. Review.PMID: 14502107 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.

    Ramsdell JW, Braunstein SN, Stephens JM, Bell CF, Botteman MF, Devine ST.

    Pharmacoeconomics. 2003;21(11):819-37.PMID: 12859222 [PubMed - indexed for MEDLINE]Related articles

    19.

    Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000.

    Icks A, Rathmann W, Haastert B, Gandjour A, Holle R, John J, Giani G; KORA Study Group.

    Diabet Med. 2007 May;24(5):473-80. Epub 2007 Mar 22.PMID: 17381502 [PubMed - indexed for MEDLINE]Related articles

    20.

    Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China.

    Xie X, Vondeling H.

    Value Health. 2008 Mar;11 Suppl 1:S23-32.PMID: 18387063 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity